At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVS Novartis AG
Market Closed 04-26 16:00:00 EDT
97.44
-1.62
-1.64%
盘后97.44
+0.000.00%
18:14 EDT
High98.22
Low97.44
Vol1.56M
Open97.76
D1 Closing99.06
Amplitude0.79%
Mkt Cap198.82B
Tradable Cap190.52B
Total Shares2.04B
T/O152.85M
T/O Rate0.08%
Tradable Shares1.96B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.